Oncolytics Biotech Inc. (TSE:ONC – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as C$0.86 and last traded at C$0.86, with a volume of 47955 shares. The stock had previously closed at C$0.89.
Oncolytics Biotech Price Performance
The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The business’s fifty day simple moving average is C$1.06 and its 200 day simple moving average is C$1.29. The stock has a market cap of C$69.37 million, a price-to-earnings ratio of -2.51 and a beta of 1.35.
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Articles
- Five stocks we like better than Oncolytics Biotech
- 3 Monster Growth Stocks to Buy Now
- Everything About Amazon Stock Signals a Buy—Time to Load Up?
- Differences Between Momentum Investing and Long Term Investing
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- Election Stocks: How Elections Affect the Stock Market
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
